Increased PD-L1 Expression in HER2-Positive Breast Cancer without Pathologic Complete Response to Neoadjuvant Therapy

被引：0
|
作者：
Yang, Fei [1 ]
Song, Juhee [1 ]
Mino, Barbara [1 ]
Parra, Edwin R. [1 ]
Sahin, Aysegul [1 ]
Wistuba, Ignacio [1 ]
Litton, Jennifer [1 ]
Mittendorf, Elizabeth [1 ]
Wu, Yun
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
MODERN PATHOLOGY | 2018年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
321
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [41] The predictive value of tumor-infiltrating lymphocytes and PD-L1 expression on the efficacy of neoadjuvant trastuzumab plus chemotherapy in HER2-positive breast cancer
    Li, Huihui
    Shang, Mao
    Chi, Yajing
    Yin, Sha
    CANCER RESEARCH, 2021, 81 (04)
  • [42] The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab
    Peintinger, F.
    Buzdar, A.
    Kuerer, H.
    Gonzalez-Angulo, A.
    Hatzis, C.
    Pusztai, L.
    Esteva, F.
    Green, M.
    Hortobagyi, G.
    Symmans, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Predictors of pathologic complete response in HER2 positive breast cancer patients treated with neoadjuvant targeted therapy
    Rosario, Mariela Huerta
    Sahoo, Sunati
    CANCER RESEARCH, 2020, 80 (04)
  • [44] Tumor infiltrating lymphocytes as a predictor of pathologic complete response to neoadjuvant therapy in HER2 positive breast cancer
    Chargoy, Alberto Monroy
    Verduzco-Aguirre, Haydee Cristina
    Chargoy, Javier Monroy
    Espinosa-Fernandez, Jose Rodrigo
    Ojeda, Jesus Antonio Martinez
    Cabrera-Galeana, Paula
    CANCER RESEARCH, 2024, 84 (09)
  • [45] Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
    Groen, Emma J.
    van der Noordaa, Marieke E. M.
    Schaapveld, Michael
    Sonke, Gabe S.
    Mann, Ritse M.
    van Ramshorst, Mette S.
    Lips, Esther H.
    Peeters, Marie-Jeanne T. F. D. Vrancken
    van Duijnhoven, Frederieke H.
    Wesseling, Jelle
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 213 - 224
  • [46] Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
    Emma J. Groen
    Marieke E. M. van der Noordaa
    Michael Schaapveld
    Gabe S. Sonke
    Ritse M. Mann
    Mette S. van Ramshorst
    Esther H. Lips
    Marie-Jeanne T. F. D. Vrancken Peeters
    Frederieke H. van Duijnhoven
    Jelle Wesseling
    Breast Cancer Research and Treatment, 2021, 189 : 213 - 224
  • [47] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    CANCER RESEARCH, 2022, 82 (04)
  • [48] Review of the status of neoadjuvant therapy in HER2-positive breast cancer
    Dowling, Gavin P.
    Keelan, Stephen
    Toomey, Sinead
    Daly, Gordon R.
    Hennessy, Bryan T.
    Hill, Arnold D. K.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [49] Application of capture-based sequencing in predicting pathologic response to neoadjuvant therapy in HER2-positive breast cancer.
    Ma, Fei
    Wang, Wenna
    Li, Jin
    Chang, Lianpeng
    Guan, Yan-Fang
    Yi, Zongbi
    Fan, Ying
    Guan, Xiuwen
    Xia, Xuefeng
    Yi, Xin
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy Association with pathologic complete response
    Dong, Jing-Min
    Wang, Hong-Xia
    Zhong, Xiao-Fei
    Xu, Kun
    Bian, Jia
    Feng, Yan
    Chen, Liang
    Zhang, Lin
    Wang, Xia
    Ma, De-Jing
    Wang, Bin
    MEDICINE, 2018, 97 (43)
12345